Use of telomerase to create bioengineered tissues

Annals of the New York Academy of Sciences

Volumn 1057, Issue , 2005, Pages 479-491

  Shay, Jerry W ^a   Wright, Woodring E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aging; Bioengineered tissue; Cell division; Cell proliferation; Senescence; Telomerase; Telomeres

Indexed keywords

REPETITIVE DNA; RIBONUCLEOPROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN;

BIOENGINEERING; BREAST EPITHELIUM; CARCINOGENESIS; CATALYSIS; CELL IMMORTALIZATION; CHROMOSOME; CONFERENCE PAPER; CORNEA CELL; DNA SEQUENCE; DNA STRAND; DNA SYNTHESIS; ENDOTHELIUM CELL; FIBROBLAST; GERM LINE; HUMAN; KERATINOCYTE; LIFESPAN; MYOMETRIUM; PIGMENT EPITHELIUM; SENESCENCE; SKIN CELL; TELOMERE; TISSUE ENGINEERING;

EID: 32244447211     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1356.037     Document Type: Conference Paper

References (61)

1. MULLER, H.J. 1962. The remaking of chromosomes. In Studies of Genetics: The Selected Papers of H.J. Muller, pp 384-408. Indiana University Press. Bloomington.
2. MCCLINTOCK, B. 1941. The stability of broken ends of chromosomes in Zea mays. Genetics 26: 234-282.
3. CAMPISI, J. et al. 2001. Cellular senescence, cancer, and aging: the telomere connection. Exp. Gerontol. 36: 1619-1637.
4. CAWTHON, R.M. et al. 2003. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361: 393-395.
5. WU, X. et al. 2003. Telomere dysfunction: a potential cancer predisposition factor. J. Natl. Cancer Inst. 95: 1211-1218.
6. SLAGBOOM, P. E., S. DROOG & D.I. BOOMSMA. 1994. Genetic determination of telomere size in humans: a twin study of three age groups. Am. J. Hum. Genet. 55: 876-882.
7. SHAY, J.W. & W.E. WRIGHT. 2002. Historical claims and current interpretations of replicative aging. Nat. Biotech. 20: 682-688.
8. SHAY, J.W. & W.E. WRIGHT. 2000. Hayflick, his limit, and cellular aging. Nat. Rev. Mol. Cell Biol. 1: 72-76.
9. HARLEY, C.B., A.B. FUTCHER & C.W. GREIDER. 1990. Telomeres shorten during aging. Nature 345: 458-460.
10. WRIGHT, W.E. & J.W. SHAY. 2001. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev. 11: 98-103.
11. FELDSER, D.M., J.A. HACKETT & C.W. GREIDER. 2003. Telomere dysfunction and the initiation of genome instability. Nat. Rev. Cancer 3: 623-627.
12. MASER, R.S. & R.A. DEPINHO. 2002. Connecting chromosomes, crisis, and cancer. Science 297: 565-569.
13. SHAY, J.W. 2003. Telomerase therapeutics: telomeres recognized as a DNA damage signal. Clin. Can. Res. 9: 3521-3525.
14. DE LANGE, T. & T. JACKS. 1999. For better or worse? Telomerase inhibition and cancer. Cell 98: 273-275.
15. HAHN W.C. et al. 1999. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5: 1164-1170.
16. HERBERT, B.-S. et al. 1999. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA 96: 14276-14281.
17. KELLAND, L.R. 2001. Telomerase: biology and phase I trials. Lancet Oncol. 2: 95-102.
18. KEITH, W.N. et al. 2004. Drug insight: cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat. Clin. Pract. Oncol. 1: 1-9.
19. NEIDLE S. & G. PARKINSON. 2002. Telomere maintenance as a target for anticancer drug discovery. Nat. Rev. Drug Disc. 1: 383-393.
20. SHAY J.W. & W.E. WRIGHT. 1996. Telomerase activity in human cancer. Curr. Opin. Oncol. 8: 66-71.
21. VONDERHEIDE, R.H. 2002. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21: 674-679.
22. WHITE, L., W.E. WRIGHT & J.W. SHAY. 2001. Telomerase inhibitors. Trends Biotechnol. 3: 146-149.
23. SHAY, J.W. & W.E. WRIGHT. 2002. Telomerase: a target for cancer therapy. Cancer Cell 2: 257-265.
24. MEEKER, A.K. et al. 2004. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 10: 317-326.
25. RUDOLPH, K.L. et al. 2001. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28: 155-159.
26. O'SULLIVAN, J.N. et al. 2002. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 32: 280-284.
27. FARAZI, P.A. et al. 2003. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 63: 5021-5027.
28. OKUDA, K. et al. 2000. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 152: 391-398.
29. BENETOS, A. et al. 2001. Telomere length as an indicator of biologic aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 37: 381-385.
30. VON ZGLINICKI, T. et al. 2000. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? Lab. Invest. 80: 1739-1747.
31. EPEL, E.S. et al. 2004. Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. USA 101: 17312-17315.
32. YANG, L. et al. 2001. Telomere shortening and decline in replicative potential as a function of donor age in human adrenocortical cells. Mech Ageing Dev. 122: 1685-1694.
33. Aviv, A. 2004. Telomeres and human aging: facts and fibs. Sci. Aging Knowl. Environ. 51: 43.
34. GREIDER, C.W. & E.H. BLACKBURN. 1985. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405-413.
35. WRIGHT, W.E. et al. 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18: 173-179.
36. KIM, N.W. et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
37. SHAY, J.W. & S. BACCHETTI. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer 33: 787-791.
38. MORIN, G.B. 1989. The human telomerase terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59: 521-529.
39. NUGENT, C.I. & V. LUNDBLAD. 1998. The telomerase reverse transcriptase: components and regulation. Genes Dev. 12: 1073-1085.
40. Zou, Y. et al. 2004. Does a sentinel or groups of short telomeres determine replicative senescence? Mol. Biol. Cell 15: 3709-3718.
41. SHAY, J.W. & W.E. WRIGHT. 2004. Telomeres are double-strand DNA breaks that are hidden from DNA damage responses. Mol. Cell 14: 420-421.
42. YAMAGUCHI, H. et al. 2005. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N. Engl. J. Med. 352: 1413-1424.
43. MITCHELL, J.R., E. WOOD & K.A. COLLINS. 1999. A telomerase component is defective in the human disease dyskeratosis congenita Nature 402: 551-555.
44. SHAY, J.W. & W.E. WRIGHT. 1999. Telomeres in dyskeratosis congenita. Nat. Genet. 36: 437-438.
45. SHAY, J.W. & W.E. WRIGHT. 2004. Mutant dyskerin ends relationship with telomerase. Science 286: 2284-2285.
46. VULLIAMY, T. et al. 2001. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413: 432-435.
47. HEISS, N.S. et al. 1998. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19: 32-38.
48. FOGARTY, P.F. et al. 2003. Late presentation of dyskeratosis congenital as apparently acquired aplastic anemia due to mutations in telomerase RNA. Lancet 362: 1628-1630.
49. STEINERT, S., SHAY, J.W. & W.E. WRIGHT. 2000. Transient expression of human telomerase (hTERT) extends the life span of normal human fibroblasts. Biochem. Biophys. Res. Com. 273: 1095-1098.
50. OUELLETTE, M.M. et al. 2000. Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J. Biol. Chem. 275: 10072-10076.
51. HEMANN M.T. et al. 2001. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107: 67-77.
52. SHAY, J.W. & W.E. WRIGHT. 2004. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 25: 1-8.
53. BODNAR, A.G. et al. 1998. Extension of lifespan by introduction of telomerase in normal human cells. Science 279: 349-352.
54. MORALES, C.P. et al. 1999. Lack of cancer-associated changes in human fibroblasts after immortalization with telomerase. Nat. Gen. 21: 115-118.
55. SHAY, J.W. & W.E. WRIGHT. 2000. The use of "telomerized" cells for tissue engineering. Nat. Biotech. 18: 22-23.
56. ROBERTSON, D.M. et al. 2005. Characterization of growth and differentiation in a telomerase-immortalized human corneal epithelial cell line. Invest. Ophthalmol. Visual Sci. 46: 470-478.
57. VAUGHAN, M.B. et al. 2004. A reproducible laser-wounded skin equivalent model to study the effect of aging in vitro. Regeneration Med. 2: 99-110.
58. VAUGHAN, M.B. et al. 2005. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation In press.
59. THOMAS, M., L. YANG & P.J. HORNSBY. 2000. Formation of normal functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase (TERT). Nat. Biotechnol. 18: 39-42.
60. THOMAS, M., S.R. NORTHRUP & P.J. HORNSBY. 1997. Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands. Nat. Med. 3: 978-983.
61. POH, M. et al. 2005. Blood vessels engineered from human cell. Lancet 365: 2122-2124.